Biopharma

In a significant development for the biopharmaceutical landscape, Tolerance Bio, Inc. has announced the successful closure of its oversubscribed $17.2 million seed financing round. Spearheaded by Columbus Venture Partners, this funding will accelerate the company’s innovative work on thymus preservation, regeneration, and manipulation therapies aimed at treating a range of immune-mediated diseases. Founded by industry…

In a significant advancement for ophthalmic medicine, RevOpsis Therapeutics, a pioneering biopharmaceutical firm, has been awarded a Small Business Innovation Research (SBIR) grant exceeding $1.8 million from the National Eye Institute (NEI), part of the National Institutes of Health (NIH). This funding will bolster the development of their lead asset, RO-104, aimed at treating neovascular…

In a remarkable advancement for sustainable biopharmaceuticals, Belgian company Bio-Sourcing has successfully secured €12.5 million from the European Innovation Council (EIC) Accelerator. This funding comprises €2.5 million in grants and €10 million in equity, aimed at enhancing the company’s innovative BioMilk platform, which is poised to redefine the production of biotherapeutics, particularly monoclonal antibodies. The…

PhoreMost, the cutting-edge UK biopharmaceutical enterprise specializing in innovative drug development, has successfully closed an impressive £33 million Series B funding round. This latest round, which saw significant oversubscription, underscores the growing confidence in PhoreMost’s pioneering approach to addressing previously untargetable disease mechanisms. Central to PhoreMost’s strategy is their revolutionary SITESEEKER platform. This technology excels…

Lario Therapeutics, a pioneering biopharmaceutical firm dedicated to advancing precision medicines for epileptic and neurological disorders, has been awarded a substantial $6 million USD grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This funding is earmarked to propel Lario’s preclinical research into CaV2.3 calcium channel inhibitors, heralded as a novel approach to…